Glaucoma Sufferers Have New Treatment Option
The United States’ Food and Drug Administration (FDA) has recently approved another treatment option for intraocular pressure. Intraocular pressure is the cause of glaucoma one of the leading causes of blindness in the United States.
The new drug will be brand-named Zioptan, with its main medicinal ingredient being a prostaglandin analog called tafluprost. Like other prostaglandins, such as the number one selling latanoprost, Zioptan will be prescribed as an ophthalmic solution (eyedrops). Opthamalogists usually prescribe prostaglandins for a once-daily application. Zioptan’s most common side effect is a darkening of the pigmentation of the iris and areas around the eyes. The darkening of the iris is most likely a permanent occurrence.
Prostaglandin analogs are designed to increase fluid drainage in the eye, therefore reducing the pressure on the optic nerve. It is this pressure which over time permanently narrows the visual field. If left unchecked, this narrowing will cause full blindness.
Talk to your doctor about Zioptan’s approval. They will be able to decide if you should risk switching from Xalatan, the number one selling glaucoma medication.
To see the FDA’s original release, click here.